

Appendix A

Page 1 of 2

Please amend the claims as follows:

7. (Amended) Cells according to [any of claim] claim 4 [to 6], wherein said virus is Epstein-Barr virus, the origin of replication is OriP and the activating factor is EBNA-1.
8. (Amended) Cells according to [any of claims from] claim 1 [to 7], wherein the encapsidation signal of the adenovirus defective genome of the first unit is inactivated by total or partial deletion.
9. (Amended) Cells according to [any of claims from] claim 1 [to 8], wherein the non-structural regions of the adenovirus defective genome of the first unit is inactivated by total or partial deletion.
10. (Amended) Cells according to [any of claim] claim 1 [to 9], wherein the inactivated regions of the first unit are selected from the group consisting of E1, E2 and E4.
15. (Amended) Cells according to [any one of claims] claim 1 [to 14] wherein the viral regions of the first genic unit is operatively linked to at least one regulatory element enabling the tight control of the expression of said regions.
16. (Amended) Cells according to [any one of claims] claim 1 [to 15] wherein the promoter on the second genic unit is the tetracycline operator.
17. (Amended) Cells according to [any one of claims] claim 1 [to 16] wherein the viral regions in the second genic unit are operatively linked to elements regulating the expression of said regions.

Appendix A

Page 2 of 2

18. (Amended) Cells according to [any one of claims] claim 1 [to 17] wherein the adenovirus defective genome of the first unit is totally or partially constituted by the genome of a human adenovirus.

20. (Amended) Cells according to [any of claims] claim 1 [to 19], wherein the viral regions of the second genic unit, are totally or partially constituted by the viral regions of a human adenovirus.

22. (Amended) Cells for the production of helper dependent adenoviral vectors including the first genic unit as defined in [any of the claims] claim 1 [to 21].

23. (Amended) Cells for the production of helper dependent adenoviral vectors, including the second genic unit as defined in [any of the claims] claim 1 [to 21].

24. (Amended) The cells according to [any of claims] claim 1 [to 23], wherein said cells are mammalian cells.

27. (Amended) Use of the cells according to [anyone of the claims from] claim 1 [to 25], for the production of helper dependent adenoviral vectors including at least a gene of interest.